Strategic Early Material Generation for Accelerated Process Development

Rapid access to early-stage material is critical for biologics development, especially as molecular complexity increases and timelines expand. Generating scalable, high-quality material early helps streamline developability assessments and process development.

In this webinar, Samsung Biologics presents its strategy for early material generation, integrating it with cell line development (CLD), early optimization, and stable expression platforms. This approach delivers consistent, production-relevant material—nearly equivalent to single-clone sources—while reducing variability, time, and complexity.

Learn how this streamlined workflow accelerates development from sequence to material, supports downstream activities, and improves efficiency. Case studies will highlight scalable production from flask to bioreactor and the impact of early decisions on timelines and costs.

Key benefits:
– Faster, more efficient early-stage biologics development
– Improved scalability through alignment with CLD
– Reliable material supply for process and formulation studies